209 related articles for article (PubMed ID: 28370072)
1. Expression profiling of Sudanese visceral leishmaniasis patients pre- and post-treatment with sodium stibogluconate.
Salih MAM; Fakiola M; Lyons PA; Younis BM; Musa AM; Elhassan AM; Anderson D; Syn G; Ibrahim ME; Blackwell JM; Mohamed HS
Parasite Immunol; 2017 Jun; 39(6):. PubMed ID: 28370072
[TBL] [Abstract][Full Text] [Related]
2. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
[TBL] [Abstract][Full Text] [Related]
3. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.
Musa AM; Khalil EA; Mahgoub FA; Elgawi SH; Modabber F; Elkadaru AE; Aboud MH; Noazin S; Ghalib HW; El-Hassan AM;
Trans R Soc Trop Med Hyg; 2008 Jan; 102(1):58-63. PubMed ID: 17963805
[TBL] [Abstract][Full Text] [Related]
4. Circulating immune complexes (IC) and IC-induced levels of GM-CSF are increased in sudanese patients with acute visceral Leishmania donovani infection undergoing sodium stibogluconate treatment: implications for disease pathogenesis.
Elshafie AI; Ahlin E; Mathsson L; ElGhazali G; Rönnelid J
J Immunol; 2007 Apr; 178(8):5383-9. PubMed ID: 17404324
[TBL] [Abstract][Full Text] [Related]
5. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
6. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
[TBL] [Abstract][Full Text] [Related]
7. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study.
Das S; Mandal R; Rabidas VN; Verma N; Pandey K; Ghosh AK; Kesari S; Kumar A; Purkait B; Lal CS; Das P
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005060. PubMed ID: 27776123
[TBL] [Abstract][Full Text] [Related]
8. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
9. Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment.
el Hassan AM; Ghalib HW; Zijlstra EE; Eltoum IA; Satti M; Ali MS; Ali HM
Trans R Soc Trop Med Hyg; 1992; 86(3):245-8. PubMed ID: 1329273
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.
Veeken H; Ritmeijer K; Seaman J; Davidson R
Trop Med Int Health; 2000 May; 5(5):312-7. PubMed ID: 10886792
[TBL] [Abstract][Full Text] [Related]
11. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
Mondal D; Kumar A; Sharma A; Ahmed MM; Hasnain MG; Alim A; Huda MM; Rahman R; Alvar J; Ahmed BN; Haque R
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
[TBL] [Abstract][Full Text] [Related]
12. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
Ritmeijer K; Veeken H; Melaku Y; Leal G; Amsalu R; Seaman J; Davidson RN
Trans R Soc Trop Med Hyg; 2001; 95(6):668-72. PubMed ID: 11816442
[TBL] [Abstract][Full Text] [Related]
13. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
Karki P; Koirala S; Parija SC; Sethi M; Das ML
Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
[TBL] [Abstract][Full Text] [Related]
14. Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patients.
Salih MA; Fakiola M; Abdelraheem MH; Younis BM; Musa AM; ElHassan AM; Blackwell JM; Ibrahim ME; Mohamed HS
BMC Infect Dis; 2014 Dec; 14():662. PubMed ID: 25466928
[TBL] [Abstract][Full Text] [Related]
15. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Dube A; Singh N; Sundar S; Singh N
Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
[TBL] [Abstract][Full Text] [Related]
16. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M
Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis.
Ramesh V; Kumar J; Kumar D; Salotra P
Indian J Dermatol Venereol Leprol; 2010; 76(2):138-44. PubMed ID: 20228542
[TBL] [Abstract][Full Text] [Related]
19. Post-kala-azar dermal leishmaniasis mimicking leprosy: experience with 4 patients, with some unusual features in 1.
Dhar S; Kaur I; Dawn G; Sehgal S; Kumar B
Lepr Rev; 1995 Sep; 66(3):250-6. PubMed ID: 7500822
[TBL] [Abstract][Full Text] [Related]
20. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
